<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01402232</url>
  </required_header>
  <id_info>
    <org_study_id>Y20110721</org_study_id>
    <nct_id>NCT01402232</nct_id>
  </id_info>
  <brief_title>REduction of rIsk for Contrast Induced Nephropathy</brief_title>
  <acronym>REICIN-RESCIND</acronym>
  <official_title>REduction of rIsk for Contrast-Induced Nephropathy (REICIN) Study:RESCIND-P (Prospective Observational Study for REduction of contraSt-induced Nephropathy and Cardiaovascular Events followINg carDiac Catheterization)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou General Hospital of Guangzhou Military Command</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dongguan Kanghua Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dongguan People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maoming People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Futian People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Longyan City First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Kashgar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangdong Provincial People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The REduction of rIsk for Contrast-Induced Nephropathy (REICIN) study is the largest
      prospective multicenter data base for CIN flowing coronary angiography (CAG) or percutaneous
      coronary intervention (PCI). The REICIN study has the potential to characterize contemporary
      CIN incidence, modified risk factors and prognosis, so that to identify strategiaes to reduce
      risk of CIN following CAG/PCI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter prospective observational study collecting data on over 5000 CAG
      patients admitted to department of cardiology in 12 hospitals from January 2013. Data will be
      collected for more than 1 year on all patients undergoing CAG with or without PCI older than
      18 years without baseline end-stage renal failure needing renal replacement therapy or renal
      transplantation. Data to be collected includes demographic information, admission diagnoses
      and co-morbidities, biomarkers and details on preventive hydration and medications used
      Contrast-induced nephropathy (CIN) is the primary endpoint, defined as a ≥ 0.5 mg/dL or 25%
      increase in serum creatinine (SCr) from baseline during the first 48 to 72 hours after the
      procedure.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>contrast-induced nephropathy</measure>
    <time_frame>48-72 h</time_frame>
    <description>Contrast-Induced Nephropathy was defined as a ≥ 0.5 mg/dL or 25% increase in serum creatinine from baseline during the first 48 to 72 hours after the procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>contrast-induced acute kidney injury (CI-AKI0.3)</measure>
    <time_frame>48h</time_frame>
    <description>defined as a ≥ 0.3 mg/dL absolute increase in serum creatinine from baseline during the first 48 hours after the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystatin C based CI-AKI (CI-AKIcyc)</measure>
    <time_frame>24-48h</time_frame>
    <description>defined as a ≥10% absolute increase in serum cystatin C during the first 24 hours after the procedure and and a ≥ 0.3 mg/dL absolute increase in serum creatinine from baseline during the first 48 hours after the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of eGFR, calculate based on CrCl and serum cystatin C</measure>
    <time_frame>48-72 h</time_frame>
    <description>The eGFRcreatinine-cystatin C was calculated by the 2012 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) cystatin C equation: 135 × min(Scr/κ, 1)α × max(Scr/κ, 1)−0.601 × min(Scys/0.8, 1)−0.375 × max (Scys/0.8, 1)−0.711 × 0.995Age [× 0.969 if female] [× 1.08 if black], where Scr is serum creatinine, Scys is serum cystatin C, κ is 0.7 for females and 0.9 for males, α is −0.248 for females and −0.207 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistent CI-AKI (CI-AKIp)</measure>
    <time_frame>3 months</time_frame>
    <description>defined as residual impairment of renal function indicated by a ≥ 25% reduction in creatinine clearance at 3 months in comparison with baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital major adverse cardiovascular and clinical events</measure>
    <time_frame>In-hospital</time_frame>
    <description>all-cause mortality (cardiovascular and noncardiovascular), required renal replacement therapy (RRT), cardiovascular events (acute myocardial infarction, acute heart failure，cardiac shock, heart/ventricular septal rupture,clinical arrhythmia), Cerebrovascular events (Stroke), and bleeding (TIMI grade) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up major adverse cardiovascular and clinical events</measure>
    <time_frame>&gt;=1 year</time_frame>
    <description>all-cause mortality, RRT, re-hospitalization, cardiovascular events, cerebrovascular events, and bleeding.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Contrast Induced Nephropathy</condition>
  <arm_group>
    <arm_group_label>coronary angiography</arm_group_label>
    <description>We recruit all consecutive patients who were undergoing coronary angiography or percutaneous coronary intervention.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        We reviewed all consecutive patients who were undergoing coronary angiography
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients referred to CAG or PCI;

          2. Age ≥ 18 years

          3. Submit informed consent and adhere to the study protocol

        Exclusion Criteria:

          1. Fail to undergo CAG/PCI or die during the procedure；

          2. End-stage renal diseases or renal replacement；

          3. Pre-procedural unstable renal funciton (acute increase in serum creatinine more than
             0.5mg/ml in the past 24 h)；

          4. Intravascular administration of a contrast medium within the previous 48 hours；

          5. Allergic to contrast medium;

          6. Pregnancy, lactation or malignant tumoror life expectancy&lt; 1 year;

          7. The use of renal toxicity drugs (non-steroidal anti-inflammatory drugs, aminoglycoside
             drugs, cyclosporine, cisplatin etc) within 48 h before cardiac catheter surgery and
             the whole process of the research;

          8. Refer to receive renal artery angiography or surgical valve replacement in patients
             with rheumatic heart disease； For exclusion creteria 7, patients admited and taked
             aspirin are included in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Liu, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Guangdong Cardiovascular Institute,Guangdong General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shiqun Chen, MS</last_name>
    <role>Study Director</role>
    <affiliation>Guangdong Cardiovascular Institute,Guangdong General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaihong Chen</name>
      <address>
        <city>Longyan</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guoliang Jia</name>
      <address>
        <city>Dongguan</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jianfeng Ye</name>
      <address>
        <city>Dongguan</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jian Qiu</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jingfeng Wang</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ken Wu</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yuqing Hou</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhiming Du</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510100</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yan Liang</name>
      <address>
        <city>Maoming</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guifu Wu</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiaoguang Zhou</name>
      <address>
        <city>Kashi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 25, 2011</study_first_submitted>
  <study_first_submitted_qc>July 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2011</study_first_posted>
  <last_update_submitted>August 1, 2018</last_update_submitted>
  <last_update_submitted_qc>August 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong Provincial People's Hospital</investigator_affiliation>
    <investigator_full_name>Jiyan Chen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>contrast-induced nephropathy</keyword>
  <keyword>contrast medium</keyword>
  <keyword>creatinine clearance</keyword>
  <keyword>coronary angiography</keyword>
  <keyword>diabetes</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>predictive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

